If you haven’t been paying attention, medical psychedelics are on the rise, with the new industry gaining an impressive foothold even before legalizations occur. In this new move, Wesana Health will acquire Psytech, Inc., giving the company new strength to dominate this new emerging market.
The world changes quickly. Not only is Wesana Health about to acquire PsyTech, Inc., signaling even more growth in the medical psychedelics industry, but our favorite psychedelic – cannabis – has more options for consumers than ever. Take Delta 10, THCV, THC-O or Delta-8 THC for example. This half-brother of delta-9 THC provides users with a slightly less intense psychoactive high, doesn’t produce anxiety, and leaves users clear-headed and energetic. This is amazing for anyone who wants a different option. Check out our array of delta-8 THC products – along with tons of other compounds offered, and take advantage of new drug technologies and formulations.
Subscribe to the Psychedelics Weekly newsletter below:
Wesana will acquire Psytech, Inc., what will this mean?
Wesana Health Holdings, is a life sciences company that specializes in developing and delivering therapies for neurological health issues. The Chicago-based company looks to help patients overcome the damage of physical brain trauma which results in neurological, psychological, and mental health problems. The company was founded recently, in 2020, and looks to develop therapeutic solutions using psychedelic therapies including drugs like: Ketamine (and esketamine, which is currently legal), mescaline, MDMA, and psilocybin.
Psychedelitech, Inc. (PsyTech, Inc.) is a company specializing in the medical psychedelics industry, which provides clinical tools and education, as well as clinical care. The company promotes psychedelic-assisted therapy, novel methods of care and the tools to go along with them, and integrative ways for mental healthcare delivery. The company focuses a lot on the use of psilocybin therapies. The company has three parts: Tovana Solutions – a SaaS platform, Tovana Clinics – which provides a psychiatric care network, and PsyTech Connect – a community for psychedelic practitioners.
It was announced on June 13th, 2021, that Wesana Health would acquire PsyTech for $21 million, making PsyTech a completely owned subsidiary of Wesana. This will give Wesana access to all three parts of PsyTech. Wesana is looking to expand its efforts into neurological healthcare. According to CEO Daniel Carcillo (who is also a former NHL hockey player and two-time winner of the Stanley Cup), Wesana is working on new treatments and medications to treat traumatic brain injuries. He made this statement about the acquisition: